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ABSTRACT 
Rovabio
® Spiky is an enzyme preparation, available in solid and liquid forms, of endo-1,4-beta-xylanase and 
endo-1,3(4)-beta-glucanase. The enzymes present in the additive are produced by two strains of Penicillium 
funiculosum,  one  of  them  genetically  modified.  The  additive  is  intended  to  be  used  as  a  feed  additive  for 
chickens for fattening, chickens reared for laying and other minor poultry species (for fattening and reared for 
laying). None of the production strains was detected in their respective products. The additive does not give rise 
to safety concerns with regard to the genetic modification. No recombinant DNA was detected in the product 
obtained from the genetically modified strain of P. funiculosum. Based on the results of a tolerance trial in 
chickens for fattening, the FEEDAP Panel concludes that the additive is safe for chickens for fattening under the 
recommended conditions of use. This conclusion can be extended to chickens reared for laying and can be 
extrapolated  to  minor  poultry  species  for  fattening  or  reared  for  laying.  Based  on  the  outcome  of  the 
toxicological studies performed with the products of fermentation used to formulate the additive, the additive is 
of no concern regarding consumer safety. The additive is not irritant to the skin or eyes. In the absence of data, it 
should be considered a potential skin sensitiser and potentially harmful if inhaled. No risks to the environment 
are expected from the use of the additive in animal nutrition. Based on the results obtained in three efficacy 
studies,  the  FEEDAP  Panel  concludes  that  the  additive  has  the  potential  to  be  efficacious  in  chickens  for 
fattening at the minimum recommended dose. This conclusion can be extended to chickens reared for laying and 
can be extrapolated to minor poultry species for fattening or reared for laying. 
© European Food Safety Authority, 2014 
KEY WORDS 
zootechnical additive, digestibility enhancers, endo-1,4-beta-xylanase, endo-1,3(4)-beta-glucanase, poultry 
                                                       
1  On request from European Commission, Question No EFSA-Q-2013-00750, adopted on 2 July 2014. 
2  Panel  members:  Gabriele  Aquilina,  Vasileios  Bampidis,  Maria  De  Lourdes  Bastos,  Lucio  Guido  Costa,  Gerhard 
Flachowsky, Mikolaj Antoni Gralak, Christer Hogstrand , Lubomir Leng, Secundino López -Puente, Giovanna Martelli, 
Baltasar Mayo, Fernando Ramos, Derek Renshaw, Guido Rychen, Maria Saarela, Kristen Sejrsen, Patrick Van Beelen, 
Robert John Wallace and Johannes Westendorf. Correspondence: FEEDAP@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on  Enzymes, including Paul Brantom, 
Noël Dierick and Ingrid Halle, and the Working Group on Genetically Modified Microorganisms , including Pier Sandro 
Cocconcelli, Boet Glandorf, Lieve Herman, Christoph Tebbe and Sirpa Kärenlampi , for the preparatory work on this 
scientific opinion. 
 Rovabio
® Spiky for chickens  
 
EFSA Journal 2014;12(7):3793  2 
SUMMARY 
Following  a  request  from  the  European  Commission,  the  Panel  on  Additives  and  Products  or 
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on Rovabio
® 
Spiky (endo-1,4-beta-xylanase (EC 3.2.1.8) and endo-1,3(4)-beta-glucanase (EC 3.2.1.6)) as a feed 
additive for chickens for fattening, chickens reared for laying and other minor poultry species (for 
fattening and reared for laying). 
This additive is prepared by combining two products of fermentation obtained from two strains of 
Penicillium funiculosum (Talaromyces versatilis sp. novus), one of them non-genetically modified and 
the other genetically modified. The additive is available in solid and liquid forms. Both formulations 
are considered equivalent in terms of safety and efficacy for the target species. 
None of the production strains was detected in their respective products. The additive does not give 
rise to safety concerns with regard to the genetic modification of one of the production strains. No 
recombinant DNA was detected in the product of fermentation obtained from the genetically modified 
strain of P. funiculosum. 
The results obtained in the tolerance trial in chickens for fattening showed that the birds tolerated well 
200-fold the minimum recommended dose; therefore, the FEEDAP Panel concludes that the additive 
is safe for chickens for fattening under the conditions of use. This conclusion can be extended to 
chickens reared for laying. Moreover, considering the margin of safety, the conclusion can also be 
extrapolated to minor poultry species for fattening or reared for laying. 
The  products  of  fermentation  used  for  the  preparation  of  the  additive  gave  negative  results  for 
mutagenicity.  The  results  obtained  in  sub-chronic  oral  toxicity  studies  also  raised  no  concerns. 
Therefore, based on the toxicological studies performed with the fermentation products, the additive is 
of no concern regarding consumer safety. 
The additive is not irritant to the skin or eyes. In the absence of data, it should be considered a 
potential skin sensitiser and potentially harmful if inhaled. 
No risks to the environment are expected from the use of the additive in animal nutrition. 
Based on the results obtained in three long-term trials in chickens for fattening, the FEEDAP Panel 
concludes that the additive has the potential to be efficacious at the minimum recommended dose 
(1 100 U/kg xylanase and 760 U/kg glucanase). This conclusion can be extended to chickens reared 
for laying. The mode of action of the enzymes glucanase and xylanase is well known and can be 
considered similar in all poultry species; thus, the conclusion on the efficacy in chickens for fattening 
can be extrapolated to minor poultry species for fattening or reared for laying. Rovabio
® Spiky for chickens  
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BACKGROUND 
Regulation  (EC)  No  1831/2003
4  establishes the rules governing the Community authorisation of 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 
person seeking authorisation for a feed additive or for a new use of a feed additive shall sub mit an 
application in accordance with Article 7.  
The European Commission received a request from the company ADISSEO
5 for authorisation of the 
product Rovabio
® Spiky (endo-1,4-beta-xylanase and endo-1,3(4)-beta-glucanase), when used as a 
feed additive for chickens for fattening, chickens reared for laying and other minor poultry species (for 
fattening  and  reared  for  laying)  (category:  zootechnical  additives;  functional  group:  digestibility 
enhancers) under the conditions mentioned in Table 1.  
According  to  Article  7(1)  of  Regulation  (EC)  No  1831/2003,  the  Commission  forwarded  the 
application  to  the  European  Food  Safety  Authority  (EFSA)  as  an  application  under  Article  4(1) 
(authorisation of a feed additive or new use of a feed additive). EFSA received directly from the 
applicant  the  technical  dossier  in  support  of  this  application.
6  According  to  Article  8  of  that 
Regulation, EFSA, after verifying the particulars and documents submitted by the applicant, shall 
undertake an assessment in order to determine whether the feed additive complies with the conditions 
laid down in Article 5. The particulars and documents in support of the application were considered 
valid by EFSA as of 08 October 2013. 
The  additive  Rovabio
®  Spiky  is  a  preparation  of  endo-1,4-beta-xylanase  and  endo-1,3(4)-beta-
glucanase produced by two strains of Penicillium funiculosum one not genetically modified and one 
genetically modified. This product has not been previously authorised in the European Union (EU). 
TERMS OF REFERENCE 
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the 
safety for the target animals, consumer, user and the environment and the efficacy of the product 
Rovabio
®  Spiky  (endo-1,4-beta-xylanase  and  endo-1,3(4)-beta-glucanase),  when  used  under  the 
conditions described in Table 1. 
                                                       
4  Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use 
in animal nutrition. OJ L 268, 18.10.2003, p. 29. 
5  ADISSEO, 10 Place du Général de Gaule, 92160 Antony, France. 
6  EFSA dossier reference: FAD-2013-0030. Rovabio
® Spiky for chickens  
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Table 1:   Description and conditions of use of the additive as proposed by the applicant
7  
Additive  
Endo-1,4-beta-xylanase EC 3.2.1.8 and Endo-1,3(4)-beta-glucanase EC 
3.2.1.6 
Registration number/EC No/No 
(if appropriate)  / 
Category(-ies) of additive  Zootechnical additive (4) 
Functional group(s) of additive  Digestibility enhancer (a) 
 
Description 
Composition, description 
Chemical 
formula 
Purity criteria 
(if appropriate) 
Method of analysis 
(if appropriate) 
Preparation of endo-1,4- 
beta-xylanase and endo-1,3(4)-
beta-glucanase produced from 
Talaromyces versatilis  
(basionym Penicillium 
funiculosum) and Talaromyces 
versatilis (basionym Penicillium 
funiculosum) having a minimum 
activity of: 
 
     Powder form  
- Endo-1,4-beta-xylanase: 
min. 22 000 viscometric units/g  
OR min. 2 300 DNS units/g 
- Endo-1,3(4)-beta-glucanase : 
min. 15 200 viscometric units/g 
OR min. 1 600 DNS units/g 
                 
   Liquid form 
- Endo-1,4-beta-xylanase: 
min. 5 500 viscometric units/ml 
OR min. 570 DNS units/ml 
- Endo-1,3(4)-beta-glucanase : 
min. 3 800 viscometric units/ml 
OR min. 400 DNS units/ml 
 
/  / 
- Viscosimetric method: 
based on decrease in 
viscosity produced by 
action of Endo-1,4-beta-
xylanase on xylan 
containing substrate and 
action of Endo-1,3(4)-
beta-glucanase on glucan 
substrate. 
 
 Colorimetric (DNS) 
method: based of the 
enzymatic hydrolysis of  
xylan containing substrate 
and glucan substrate 
respectively for Endo-1,4-
beta-xylanase and  Endo-
1,3(4)-beta-glucanase 
 
 
Trade name (if appropriate)  ROVABIO
® SPIKY 
Name of the holder of 
authorisation (if appropriate)  ADISSEO France S.A.S. 
 
Conditions of use 
Species  or category  
of animal 
Maximum 
Age 
Minimum content  Maximum content  Withdrawal 
period 
(if appropriate)  units/kg of complete feedingstuffs 
Chickens for 
fattening, chickens  /  Endo-1,4-beta-xylanase: 
1100 viscometric Units  /  / 
                                                       
7  This section has been edited following the confidentiality claims made by the applicant. Rovabio
® Spiky for chickens  
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reared for laying and 
minor poultry 
species (for 
fattening and reared  
for laying) 
Endo-1,3(4)-beta-
glucanase: 
760 viscometric Units 
 
Other provisions and additional requirements for the labeling 
Specific conditions or restrictions for 
use (if appropriate) 
In the directions for use of the additive and premixture, indicate the 
storage temperature, storage life, and stability to pelleting. 
Specific conditions or restrictions for 
handling (if appropriate)  Do not breath, avoid contact with skin and eye 
Post-market monitoring  
(if appropriate) 
There is no need for specific requirements for a post-market 
monitoring  plan  other  than  those  established  by  Regulations  No 
178/2002 and No 183/2005. 
ADISSEO  has  a    full  traceability  system  in  place,  including 
procedures for recalls. A free emergency contact number is printed 
in each label and also available in the Material Safety Data Sheet 
supplied to all customers. 
Specific conditions for use in 
complementary feedingstuffs  
(if appropriate) 
For  use  in  feed  rich  in  starch  and    non-starch  polysaccharides 
(mainly beta-glucans and arabinoxylans) 
 
Maximum Residue Limit (MRL) (if appropriate) 
Marker residue  Species or category of 
animal 
Target tissue(s) or 
food products 
Maximum content in 
tissues 
/  /  /  / Rovabio
® Spiky for chickens  
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ASSESSMENT 
1.  Introduction
8 
The additive Rovabio
® Spiky is a preparation of endo-1,4-beta-xylanase (xylanase: EC 3.2.1.8) and 
endo-1,3(4)-beta-glucanase  (glucanase:  EC  3.2.1.6)  and  is  available  in  solid  and  liquid  forms 
(Rovabio
® Spiky AP and Rovabio
® Spiky LC, respectively). This additive is prepared by combining 
two  products  of fermentation  obtained  from  two  strains  of  Penicillium funiculosum (Talaromyces 
versatilis sp. novus), one of them non-genetically modified and the other genetically modified. This 
additive has not been authorised in the European Union (EU) and it is intended to be used in feed for 
chickens for fattening, chickens reared for laying and other minor poultry species (for fattening and 
reared for laying) as a zootechnical additive under the functional group of digestibility enhancers. 
2.  Characterisation
9 
2.1.  Characterisation of the product 
Rovabio
® Spiky is available in solid and liquid forms and contains two main enzymatic activities, 
glucanase and xylanase. The analysis of such enzyme activities in the additive is performed following 
two  methods,  a  viscosimetric-based  method  (viscosimetric  units  (U))
10  or a method based on   the 
colour formation of released sugars with 3,5 -dinitrosalicylic acid (DNS U)
11 (for further details, see 
the Appendix). 
The solid form, Rovabio
®  Spiky  AP,  is  an  uncoated  spray-dried  light-  to  dark-beige  powder.  It 
contains 15–25 % dry products of fermentation and 75–85 % wheat flour (food grade). The product 
also contains sodium benzoate (< 0.1 %). Per gram of solid product, there is a minimum of 22 000 U 
or 2 300 DNS U of xylanase activity and 15 200 U or 1 600 DNS U of glucanase activity. The batch-
to-batch  variation  was  assessed  in  five  batches,
12
  which  showed  mean  values  of  xylanase  of 
29 147 U/g (coefficient of variation (CV) 7.7 %) and 3 120 DNS U/g (CV 5.0 %) and mean values of 
glucanase of 20 583 U/g (CV 6.0 %) and 2 261 DNS U/g (CV 3.1 %). 
Three batches of this formulation were studied for particle size and dusting potential.
13 Particle size 
distribution showed no more than 2.8 % of the particles with a diameter below 100 μm, 1.1 % below 
50 μm and with no particles below 10 μm, with a mean particle size ranging 348−456 μm. The dusting 
potential ranged from 0.04 to 0.10 g/m
3 and the dust index from 1.65 to 3.95 mg/100 g. 
The liquid form, Rovabio
® Spiky LC, is a transparent to brown fluid that contains 4–8 % (w/w) liquid 
products of fermentation, 10–30 % sorbitol, 0.1–0.4 % potassium sorbate and water up to 100 %. The 
ingredients used to formulate the product are food grade.
14
 The product also contains sodium benzoate 
(< 0.1 %).  It  is  ensured  that,  per  millilitre  of  liquid  product,  there  is  a  minimum  of  5 500 U  or 
570 DNS U of xylanase activity and 3 800 U or 400 DNS U of glucanase activity. The batch-to-batch 
variation was studied in five batches,
15 which showed mean values for xylanase of 6 525 U/mL (CV 
3.2 %) and 704 DNS U/mL (CV 3.4 %) and mean values for glucanase of 4 390 U/mL (CV 3.0 %) and 
                                                       
8  This section has been edited following the confidentiality claims made by the applicant. 
9  This section has been edited following the confidentiality claims made by the applicant. 
10 One  xylanase (or  beta-glucanase)  viscosity unit (U) is defined as the   amount of  xylanase (or  beta-glucanase)  that 
hydrolises wheat arabinoxylan (or barley beta-glucan), reducing the solution viscosity, in order to change the relative 
fluidity by one dimensionless unit per minute, at pH 5.5 and 30 °C. 
11 One xylanase (or beta-glucanase) DNS unit corresponds to the amount of xylanase (or beta -glucanase) which liberates 
from the birchwood xylan (or barley beta-glucan) one µmol of xylose (or glucose) per minute at 50 °C and pH 4.0 (or pH 
5.0). 
12 Technical dossier/Section II/Annex II.1.2. 
13 Technical dossier/Section II/Annex II.1.15. 
14 Technical dossier/Section II/Annex II.1.1. 
15 Technical dossier/Section II/Annex II.1.2. Rovabio
® Spiky for chickens  
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487 DNS U/mL (CV 3.3 %). The liquid formulation has, at 20 °C, a pH of 5.45, a relative density of 
1.1 and a mean viscosity value of 3.9 mPa·s.
16 
The carriers/stabilisers used to formulate the additive are feed materials or authorised feed additives. 
Three batches of the final formulations and/or three batches of the two products of fermentation were 
analysed for chemical and microbial contamination.
17
 Chemical contamination, measured in the final 
formulations,  included  the  analysis  of  lead  (< 0.05 mg/kg),  mercury  (< 0.005 mg/kg),  cadmium 
(< 0.02 mg/kg),  fluorine  (< 25 mg/kg)  and  arsenic  (< 0.1 mg/kg).  The  dioxin  and  dioxin-like 
polychlorinated  biphenyl  (PCB)  contents  were  also  determined.  The  mean  content  of  dioxins  in 
Rovabio
®  Spiky  AP  is  0.118 ng  polychlorinated  dibenzodioxins/-furans  (PCDD/F)  World  Health 
Organisation toxic equivalent (WHO-TEQ) (upper bound)/kg and the mean content of dioxins plus 
dioxin-like PCBs is 0.174 ng PCDD/F+PCB WHO-TEQ (upper bound)/kg. For Rovabio
® Spiky LC, 
the mean content of dioxins is 0.007 ng PCDD/F WHO-TEQ (upper bound)/kg and the mean content 
of  dioxins  plus  dioxin-like  PCBs  is  0.01 ng  PCDD/F+PCB  WHO-TEQ  (upper  bound)/kg.  The 
microbial contamination analysis performed in the final formulations and the products of fermentation 
included aerobic colony count (47 colony-forming units (CFU)/g in the solid product and < 1 CFU/mL 
in the liquid product and products of fermentation), total Enterobacteriaceae (12 CFU/g in the solid 
product and < 1 CFU/mL in the liquid product and products of fermentation), Escherichia coli, total 
coliforms, moulds and yeasts, Clostridium perfringens, sulphate-reducing anaerobic germs (5 CFU/g 
in  the  solid  product  and  1 CFU/mL  in  the  liquid  product),  coagulase-positive  staphylococci 
(< 50 CFU/g  in  the  solid  product  and  < 10 CFU/mL  in  the  liquid  product  and  products  of 
fermentation) and Salmonella spp. (absent in 25 g of both products). The applicant provided evidence 
for the absence of the production strains in three batches of the two products of fermentation.
18 The 
final formulations were also analysed for  the following  mycotoxins: aflatoxin B1, B2, G1 and G2 
(< 2 μg/kg), ochratoxin A and B (< 1 μg/kg), ochratoxin alpha (< 5 μg/kg), fumonisin B1, B2 and B3 
(< 100 μg/kg), diacetoxyscirpenol, 15-acetoxyscirpenol, neosolaniol, HT2-toxin, T2-toxin, nivalenol, 
deoxynivalenol,  fusarenon,  3-acetyl-deoxynivalenol,  15-acetyl-deoxynivalenol,  zearalenone, 
sterigmatocystin, verruculogen, citrinin, cyclopiazonic acid (< 20 μg/kg) and patulin (< 10 μg/kg). The 
absence  of  antibiotic  activity  in  three  batches  of  each  product  of  fermentation  was  shown.
19  An 
indication of the total organic solids content from the products of fermentation in the final products 
was provided.
20 
2.2.  Characterisation of the production organisms 
The enzymes contained in the additive Rovabio
® Spiky are present in two products of fermentation. 
One is produced by a non-genetically modified strain of P. funiculosum (Talaromyces versatilis sp. 
novus) and the second product of fermentation is produced by a genetically modified strain of  P. 
funiculosum (Talaromyces versatilis sp. novus).  
2.2.1.  Information  relating  to  the  genetically  modified  microorganism  Penicillium 
funiculosum  
The technical dossier contains detailed and sufficient information on the recipient microorganism, 
including aspects on the safety of the strain lineage, the origin and function of the different genetic 
elements introduced in the production strain, the genetic modification process and the genetic and 
phenotypic traits introduced. 
                                                       
16 Technical dossier/Section II/Annex II.1.17 and II.1.18. 
17 Technical dossier/Section II/Annex II.1.3 to II.1.9. 
18 Technical dossier/Section II/Annex II.1.12. 
19 Technical dossier/Section II/Annexs II.1.10. 
20 Technical dossier/supplementary information February 2014, Annex i-1. Rovabio
® Spiky for chickens  
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2.3.  Manufacturing process 
The  enzymes  contained  in  the  additive  are  obtained  from  two  fermentation  products  which  are 
produced by separate multistep processes, each consisting in fed-batch fermentation, concentration 
and purification steps. The resulting fermentation products are mixed and the final formulations are 
prepared with the addition of carriers and stabilisers. 
The production strains were not detected in three batches of the respective products. No recombinant 
DNA was detected in three independent batches of the product of fermentation from the genetically 
modified strain using PCR. 
2.4.  Stability and homogeneity 
2.4.1.  Shelf life 
The shelf life of the two final formulations was studied in
 samples (30 g or mL) of three batches, 
which were stored for a total duration of 12 months in closed low-density polyethylene zip bags (solid 
formulation) or in high-density polyethylene bottles (liquid formulation) and kept at 5 or 20 °C.
21 The 
enzyme activities were measured as U and DNS U for the two enzymes. 
For the solid preparation and after 12 months at 5 °C, recoveries of the initial enzyme activity (in U 
and DNS U) were 97 and 94 % for xylanase and 93 and 90 % for glucanase. The  samples kept at 
20 °C showed recoveries of 86 and 81 % for xylanase and 85 and 84 % for glucanase activity. 
For the liquid formulation and after 12 months at 5 °C, recoveries of the initial enzyme activity (in U 
and DNS U) were 90 and 92 % for xylanase and 100 and 89 % for glucanase. The samples kept at 
20 °C showed recoveries of 78 and 73 % for xylanase and 86 and 87 % for glucanase. 
2.4.2.  Stability of the additive in premixtures and feedingstuffs 
The stability of the solid formulation was studied in three batches of Rovabio
® Spiky AP added to a 
complete premixture for poultry (with choline chloride). Samples were kept for six months at two 
temperatures  (20  and  30 °C).
22
  The  enzyme  was  supplemented  at  264 U/g  for  xylanase  and 
33 DNS U/g for glucanase. The samples were stored in low-density polyethylene zip bags. After six 
months, mean recovery values at 20 and 30 °C were 90 and 50 % for xylanase and 90 and 87 % for 
glucanase, respectively. 
The stability of Rovabio
® Spiky AP (three batches) was investigated in mash feed for poultry for 
fattening  (introduced  via  a  premixture  which  contained  choline  chloride)  when  added  at  the 
recommended use level.
23 Samples were kept for four months at two different temperatures (20 and 
30 °C) in closed packages. After four months, the mean recoveries at 20 and 30 °C were 92 % and 
86 % for xylanase and 93 % and 82 % for glucanase, respectively. 
The liquid formulation, Rovabio
® Spiky LC (three batches), was sprayed onto pelleted feed for poultry 
for fattening at the recommended use level.
24 The stability was investigated for  four months at two 
different temperatures (20 and 30 °C) in closed packages. After four months, the mean recoveries at 20 
and 30 °C were 93 and 83 % for xylanase and 90 and 88 % for the glucanase, respectively. 
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The stability of the solid formulation (three batches) was studied when added to feed that was pelleted 
afterwards (at a temperature of 70 °C).
25 Mean recoveries after pelleting were 69 % for xylanase and 
82 % for glucanase. Samples were not investigated further. 
2.4.3.  Homogeneity 
The capacity of homogeneous distribution of the two formulations was studied in the samples, subject 
to  the  stability  studies,  including  premixture,  mash  and  pelleted  feed.  The  evaluation  of  10  sub-
samples from the premixture supplemented with Rovabio
® Spiky AP and of complete feed (mash or 
pelleted form) supplemented with the Rovabio
® Spiky AP or LC showed in all cases a CV below 5 % 
for the two enzymes. 
2.5.  Conditions of use 
Rovabio
® Spiky is proposed for use in chickens for fattening, chickens reared for laying and other 
minor  poultry  species  (for  fattening  and  reared  for  laying)  at  a  minimum  recommended  dose  of 
1 100 U xylanase and 760 U glucanase per kg feed. 
2.6.  Evaluation of the analytical methods by the European Union Reference Laboratory 
(EURL) 
EFSA has verified the EURL report as it relates to the methods used for the control of the active 
substances in animal feed. The Executive Summary of the EURL report can be found in the Appendix. 
3.  Safety
26 
3.1.  Safety aspects of the genetic modification 
The recipient organism is considered to be safe and the traits introduced by genetic modification in the 
production strain are of no concern. 
Neither  the  genetically  modified  production  strain  nor  its  recombinant  DNA  were  detected  in  its 
product  of  fermentation.  The  additive  does  not  give  rise  to  safety  concerns  with  regard  to  the 
genetically modified production strain. 
3.2.  Safety for the target species 
A total of 1 440 one-day-old male and female chicks (commercial strain) were distributed in groups of 
20 birds each (sex separated) to 72 pens and allocated to three dietary treatments (12 male and 12 
female replicates per treatment).
27 Starter and grower diets based on wheat, soya bean meal and wheat 
distillers’  dried  grain  with  solubles  were  supplemented  with  Rovabio
®  Spiky  AP  to  provide 
(xylanase/glucanase) 0/0, 1 650/1 140 (1.5× minimum recommended dose) or 220 000/152 000 (200× 
minimum recommended dose) units per kg feed. The enzyme activities were confirmed by analysis. 
The feed was offered ad libitum for 35 days, as crumble (first eight days) or as pellets (from day 8 to 
day 35). The diets included monensin and a phytase. Feed consumption and body weight of the birds 
were measured on days 21 and 35 of the study. An analysis of variance (ANOVA) was performed on 
the data obtained (including treatment, sex, block and the interaction between treatment and sex as 
effects). The mortality data were analysed with a non-parametric test. 
Mortality was low (< 2.1 %) and was not affected by the dietary treatments. Supplementation of the 
experimental diets with 200-fold the minimum recommended dose did not have adverse effects on the 
performance of the birds. Mean final body weight of the birds was about 2.10 kg per bird and was not 
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different between the dietary treatments. Total feed intake was significantly lower in the 200× dose 
group than in the other treatment groups (3 400, 3 387 and 3 341 g per bird for 0/0, 1.5× and 200×, 
respectively). The feed-to-gain ratio was improved by the enzyme supplementation at all doses (1.65, 
1.63, 1.61 for the 0/0, 1.5× and 200× doses, respectively). 
3.2.1.  Conclusions on the safety for the target species 
Based on the results obtained in the tolerance trial in chickens for fattening, the FEEDAP Panel 
concludes  that  the  additive  is  safe  for  chickens  for  fattening  at  the  dose  of  2 200  xylanase  and 
1 520 glucanase U/kg feed and therefore safe under the conditions of use proposed by the applicant. 
This conclusion can be extended to chickens reared for laying. Moreover, considering the margin of 
safety shown, the conclusion can also be extrapolated to minor poultry species for fattening or reared 
for laying. 
3.3.  Safety for the consumer 
The  studies  presented  under  this  section  were  performed  with  each  of  the  liquid  products  of 
fermentation separately (below identified as products A and B) with the exception of the acute toxicity 
study. 
3.3.1.  Acute toxicity study 
The acute toxicity of a mixture of the two products of fermentation was studied in compliance with 
OECD Guideline 423 (2001).
28 Three male and three female rats were treated by oral route (gavage) 
with a single dose of  2 000 mg/kg body weight (bw). Morbidity/mortality checks were performed 
twice daily. Clinical observations were performed before the first dosing and then daily after dosing. 
Under the experimental conditions used, the mixture did not induce any sign of toxicity. 
3.3.2.  Bacterial reverse mutation assay 
3.3.2.1.  Product of fermentation A 
The test item was tested in two independent experiments, with and without a metabolic activation 
system, S9 mix prepared from a liver post-mitochondrial fraction of rats induced with Aroclor 1254, in 
compliance with OECD Guideline 471.
29 The plate incorporation method was used except for the 
second test with the S9 mix, which was performed according to the pre -incubation method. The test 
item was tested on Salmonella Typhimurium strains TA1535, TA1537, TA98, TA100 and TA102 up 
to a maximum dose of 5 000 μg/plate, which was freely soluble and non-cytotoxic. The test item did 
not induce any increase in the number of revertants in any of the five strains, in any experiment, either 
with or without S9 mix, while the positive controls performed as expected. 
3.3.2.2.  Product of fermentation B 
The test item was tested in two independent experiments, with and without a metabolic activation 
system, S9 mix prepared from a liver post-mitochondrial fraction of rats induced with Aroclor 1254, in 
compliance with OECD Guideline 471.
30
 The plate incorporation method was used except for the 
second test with the S9 mix, which was performed according to the pre-incubation method. The test 
item was tested on Salmonella Typhimurium strains TA1535, TA1537, TA98, TA100 and TA102 up 
to a maximum dose of 5 000 μg/plate, which was freely soluble and non-cytotoxic. The test item did 
not induce any increase in the number of revertants in any of the five strains used, in any experiment, 
either with or without S9 mix, while the positive controls performed as expected. 
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3.3.3.  In vitro mammalian cell micronucleus test 
3.3.3.1.  Product of fermentation A 
An in vitro mammalian cell micronucleus test on cultured human lymphocytes was performed with the 
test  item  with  and  without  S9  mix  from  Aroclor  1254-induced  livers  in  compliance  with  OECD 
Guideline 487.
31
 Four independent experiments were performed: a 4-hour treatment followed by a 24-
hour recovery period without S9 mix (repeated twice); the same treatment schedule with S9 mix; and a 
24-hour treatment with no recovery period without the S9 mix. The highest investigated dose of the 
test item in the culture medium was 10 %. 
A statistically significant increase in the frequency of micronucleated binucleated cells was observed 
only at the highest concentration (10 %) in both four-hour experiments without the S9 mix. However, 
the tested concentration was much higher than the top level recommended by OECD Guideline 487 
(5 μL/mL) and produced an excessive cytotoxicity (≥ 64 % cytostasis); therefore, these results are not 
considered  an  indication  of  genotoxicity.  No  statistically  significant  increase  in 
micronucleated/binucleated cells was found at the other concentrations tested. 
3.3.3.2.  Product of fermentation B 
Two studies were provided. The first was an in vitro mammalian cell micronucleus test on cultured 
human lymphocytes and was performed with the test item with and without S9 mix from Aroclor 
1254-induced livers in compliance with OECD Guideline 487.
32
 Four independent experiments were 
performed: a 4-hour treatment followed by a 24-hour recovery period with and without the S9 mix and 
a 24-hour treatment with no recovery period (repeated twice). The highest investigated dose of the test 
item in the culture medium was 10 %. 
Under these experimental conditions, the results of short-term treatments with and without metabolic 
activation were clearly negative. Regarding the long-term treatment without metabolic activation, a 
marginal  and  sporadic  increase  in  the  number  of  micronucleated  cells  was  observed  at  one 
intermediate concentration, but was not confirmed at the higher dosages. Therefore, this effect was not 
attributed to genotoxic activity. 
In  the  second  study,  the  potential  of  the  test  item  to  induce  an  increase  in  the  frequency  of 
micronucleated  cells  in  L5178Y  TK+/–  mouse  lymphoma  cells  was  tested  according  to  OECD 
Guideline 487.
33 The highest investigated dose was 5  000 µg/mL. The study was performed in two 
independent experiments; five dose levels of the test item (two cultures  per dose level) were tested 
both with and without metabolic activation (S9 mix) with treatment periods of 3 and 24 hours. Each 
treatment was coupled to an assessment of cytotoxicity (determination of cell doubling). 
No noteworthy decrease in the population doubling was noted at any of the tested concentration levels 
after the 3- or 24-hour exposures without S9 mix or after the 3-hour exposures in the presence of S9 
mix. No significant increase in the frequency of micronucleated cells was noted after the 3- or 24-hour 
exposures without S9 mix or after the 3 -hour exposures in the presence of S9 mix. Under the 
experimental conditions of the study, the test item did not induce any change in the frequency of the 
micronucleated cells. 
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3.3.4.  In vivo mammalian erythrocytes micronucleus test 
3.3.4.1.  Product of fermentation A 
The potential in vivo clastogenic activity of the test item was tested using a micronucleus test in rat 
bone marrow, in compliance with OECD Guideline 474.
34
 Male and female Sprague–Dawley OFA 
strain  rats  (five  per  sex  per  dosage  group)  were  treated  orally  twice  at  24-hour  intervals  with 
2 000 mg/kg bw, followed by one sampling time 24 hours after the last treatment. No statistically 
significant increase in the frequencies of micronucleated polychromatic erythrocytes was found in the 
treated animals compared with the untreated controls. The ratio of polychromatic to normochromatic 
erythrocytes was established at the highest dose level studied and no statistically significant alteration 
in comparison with the negative control group was found. 
3.3.4.2.  Product of fermentation B 
The potential in vivo clastogenic activity of the test item was tested using a micronucleus test in rat 
bone marrow, in compliance with OECD Guideline 474.
35
 Male and female Sprague–Dawley OFA 
strain rats (five per sex per dosage group) were treated orally twice at 24-hour intervals with 500, 
1 000 and 2 000 mg/kg bw per day, followed by one sampling time 24 hours after the last treatment. 
No statistically significant increase in the number of micronuclei was noted at any tested dose. No 
statistically significant decrease in the ratio of polychromatic to normochromatic erythrocytes was 
noted in the treated groups compared with the negative control group, except a statistically significant 
decrease in the highest female treatment group. 
3.3.5.  Sub-chronic oral toxicity study 
3.3.5.1.  Product of fermentation A 
The oral toxicity of the test item was tested in Sprague–Dawley OFA rats receiving a target daily dose 
of 0, 250, 500 and 1 000 mg test item per kg bw achieved by weekly adjustment of the concentration 
in feed. Animals were under study for 13 consecutive weeks in compliance with OECD Guideline 
408.
36
 Clinical observations were performed before the first dosing and daily thereafter. A full clinical 
examination was performed once a week. The study was conducted with the full range of observations 
required by the guideline, including functional and neurobehavioural parameters, body weight, food 
consumption,  ophthalmology,  haematology,  clinical  chemistry  and  urine  analysis.  Selected  organs 
were  weighed,  fixed  and  preserved  at  necropsy  and  examined  microscopically  for  histological 
changes. 
No mortality, clinical signs or changes in body temperature were observed. There was a statistically 
significant lower body weight from day 84 in males receiving the test item at 500 mg/kg bw and 
1 000 mg/kg bw. There was no change in body weight gain in females. Males receiving the test item 
consumed more food during the first two weeks of the study, but this was not dose dependent and it 
was not observed from the third week onwards. There were no abnormalities at the ophthalmological 
examination. No changes of toxicological relevance were observed in haematology or coagulation 
parameters. 
Higher  plasma  aspartate  aminotransferase  activity  and  statistically  significant  lower  plasma  total 
protein concentration was reported in males whatever the dose, but these changes were not associated 
with microscopic changes at histopathological examination. In females receiving the test item, there 
were lower plasma creatinine concentrations and statistically significant lower plasma total protein 
concentrations whatever the dose. The differences in plasma creatinine were found only in females 
and renal creatinine clearance was not affected. The differences in plasma creatinine concentrations 
were not associated with microscopic changes at histopathological examination. There was a lower 
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sodium concentration in urine in males receiving the test item at 1 000 mg/kg bw per day. There was a 
lower absolute thymus weight in males receiving the test item, which was more marked in males 
receiving the dose of 1 000 mg/kg bw per day, which was not reflected in the relative thymus weight 
or histopathology of the thymus. In females, there was no marked change in organ weight. There were 
“abnormal contents” and gas in the small and large intestines in a few animals receiving the test item 
whatever the dose, probably resulting from increased fermentation owing to the nature of the test item. 
Histopathological analysis revealed no treatment-related changes in male and female rats receiving the 
test item at 1 000 mg/kg bw per day. 
3.3.5.2.  Product of fermentation B 
The oral toxicity of the test item was tested in Sprague–Dawley OFA rats receiving a target daily dose 
of 0, 250, 500 and 1 000 mg test item per kg bw achieved by weekly adjustment of the concentration 
in feed. Animals were under study for 13 consecutive weeks in compliance with OECD Guideline 
408.
37
 Clinical observations for this enzyme concentrate were performed before the first dosing and 
daily thereafter. A full clinical examination was performed once a week. The study was conducted 
with  the  full  range  of  observations  required  by  the  guideline,  including  functional  and 
neurobehavioural parameters, body weight, food consumption, ophthalmology, haematology, clinical 
chemistry and urine analysis. Selected organs were weighed, fixed and preserved at necropsy and 
examined microscopically for histological changes. 
No mortality related to treatment, clinical signs or changes in body temperature were observed. There 
was a statistically significant lower body weight gain from day 49 in males receiving the test item at 
500 and 1 000 mg/kg bw and, on day 90, in males receiving the test item at 250 mg/kg bw. There was 
no change in body weight gain in females. There was a lower food consumption in males receiving the 
test item at 1 000 mg/kg bw from week 5 and at 500 mg/kg bw on week 13. In females receiving the 
test item at 500 and 1 000 mg/kg bw, there was higher, and dose-dependent, food consumption. There 
was no abnormality at the ophthalmological examination. No change of toxicological relevance was 
observed in haematology and coagulation parameters. 
Plasma  alanine  aminotransferase  and  aspartate  aminotransferase  activities  were  statistically 
significantly and dose-dependently higher in males and females at all doses, while creatinine levels 
were  statistically  significantly  lower  in  males  and  protein  concentrations  were  statistically 
significantly lower in males and females at all doses. These  differences were not associated with 
microscopic changes at histopathology examination. The renal creatinine clearance appeared to be 
unchanged. No modifications in urinary parameters and organ weight were observed. Macroscopic 
analyses revealed that gas and abnormal yellow contents in the stomach and intestines of several males 
in all dosed groups (one to three animals/group) without associated microscopic changes. The gas 
observed in some parts of the digestive tract of a few animals was probably the result of increased 
fermentation owing to the nature of the test item. 
3.3.6.  Conclusions on the safety for the consumer 
The two products of fermentation used for the preparation of the additive gave negative results for 
mutagenicity. The results obtained in sub-chronic oral toxicity studies raised no concerns regarding the 
products. Therefore, based on the toxicological studies performed with the products of fermentation, 
the additive is of no concern regarding consumer safety. The carriers/stabilisers used to formulate the 
additive are feed materials or authorised feed additives and it is considered that they do not give rise to 
safety concerns. 
                                                       
37 Technical dossier/Section III/Annex III.2.10. Rovabio
® Spiky for chickens  
 
EFSA Journal 2014;12(7):3793  15 
3.4.  Safety for the user 
3.4.1.  Effects on the skin and eyes 
3.4.1.1.  Acute skin irritation 
Rovabio
® Spiky AP and Rovabio
® Spiky LC were tested for skin irritation and/or corrosion following 
a single semi-occluded application to intact skin of the rabbit in accordance with OECD Guideline 
404.
38  Three New Zealand  White rabbits were used for each test item. For the solid and liquid 
formulations, 0.5 g and 0.5 mL of the test item, respectively, were applied to the skin of the animal. 
Semi-occlusive dressings held the test item in place for three minutes, one hour  and four hours on the 
skin of the first animal and for four hours for the two other animals.  The skin was examined at 
approximately 1, 24, 48 and 72 hours after removal of the dressing. No cutaneous change was seen in 
any animal. Therefore, under the experimental conditions  used, Rovabio
® Spiky AP and Rovabio
® 
Spiky LC were found to be non-irritant to the skin of rabbits. 
3.4.1.2.  Acute eye irritation 
Rovabio
®  Spiky  AP  and  Rovabio
®  Spiky  LC  were  tested  for  acute  eye  irritation  in  rabbits  in 
accordance with OECD Guideline 405.
39 Three New Zealand White rabbits were used for each test 
item. For the solid and liquid formulations, 0. 1 g  or 0.1 mL  of the substance, respectively, was 
introduced into the conjunctival sac of the left eye of each animal. The untreated right eye served as a 
control. Any conjunctival, iris  or corneal changes were evaluated at approximately 1, 24, 48 and 72 
hours after instillation. Except for slight lacrimation and slight redness seen  one hour after treatment 
with Rovabio
® Spiky AP, no other ocular changes were recorded in any animal after instillation. 
Therefore, under the experimental conditions used, Rovabio
® Spiky AP and Rovabio
® Spiky LC were 
found to be non-irritant to the eye of rabbits. 
3.4.1.3.  Skin sensitisation study 
No specific data were provided. In the absence of data, it would be prudent to consider the additive as 
a potential skin sensitiser. 
3.4.2.  Effects on the respiratory system 
No specific data were provided. In the absence of any data on inhalation toxicity, the additive is 
considered to be potentially harmful by inhalation. 
Analysis  of  three  batches  of  the  solid  formulation  showed  that  it  contains  a  moderate  (1.1 %) 
proportion of particles of diameter less than 50 µm but none less than 10 µm. In addition, it shows a 
low dusting potential (0.04 to 0.10 g/m
3). It is therefore unlikely that the handling of this additive by 
workers will results in them being exposed to a respirable dust, although a small amount of exposure 
to dust that is less fine and so may be inhaled and trapped in the nose and upper respiratory tract may 
occur. 
Considering  the  proteinaceous  nature  of  the  active  substances  of  the  additive,  it  is  considered  a 
potential respiratory sensitiser. 
3.4.3.  Conclusions on the safety for the user 
The additive is not irritant to the skin or eyes and is to be considered a potential skin sensitiser and 
potentially harmful by inhalation. 
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3.5.  Safety for the environment 
Neither  the  genetically  modified  production  strain  nor  its  recombinant  DNA  was  detected  in  its 
product of fermentation. The additive does not pose any environmental safety concern associated with 
the genetic modification. 
The active substances of Rovabio
® Spiky are proteins, and as such will be degraded/inactivated during 
the  passage  through  the  digestive  tract  of  animals.  The  carriers/stabilisers  used  to  formulate  the 
additive are feed materials or authorised feed additives and are considered to raise no concerns for the 
environment. Therefore, no risks to the environment are expected and no further environmental risk 
assessment is required. 
4.  Efficacy for chickens for fattening 
Three trials with similar experimental designs were provided. Details on the experimental designs and 
the results obtained are presented in Table 2. 
In the three trials, male or male and female (sex separated) one-day-old chicks were distributed to pens 
and  allocated  to  two  dietary  treatments.  The  dietary  treatments  were  obtained  from  basal  diets 
supplemented with Rovabio
® Spiky LC (sprayed on the pellets) to provide (xylanase/glucanase) 0/0 or 
1 100/760 U/kg feed. The enzyme activities were confirmed by analyses. Basal diets were based on 
maize/maize distillers’ dried grain with solubles (trial 1), wheat (trial 2) or wheat/rye (trial 3) and soya 
bean  meal, they  contained  coccidiostats (diets  in  trial  2  also  contained  a  phytase)  and they  were 
offered on an ad libitum basis for 35 days. In each trial, feed intake and body weight of the birds were 
measured throughout the study and feed-to-gain ratio was calculated. An ANOVA was performed on 
the performance data using the pen as the experimental unit. The results are presented in Table 2. 
The  supplementation  of  the  diets  with  Rovabio
®  Spiky  at  the  recommended  dose  resulted  in  a 
statistically significant improvement in the body weight gain of the chickens in two trials (trials 2 and 
3) and in a better feed-to-gain ratio in all three trials. 
Table 2:   Experimental design and results of the performance trials in chickens for fattening 
Trial 
no  Sex 
Total number of birds 
(replicates/treatment × 
birds/replicate)
 
Intended dose 
xylanase/glucanase 
(U/kg)
 
Total 
feed 
intake 
(g/bird) 
Weight 
gain 
(g/bird) 
Feed 
to 
gain 
Mortality 
(%) 
1
40  ♂  840 
(21 × 20) 
0/0  2 692
  1 665  1.62
a  5.2 
1 100/760  2 642
  1 657  1.59
b  3.8 
2
41  ♂/♀  1 280 
(32 × 20) 
0/0  3 978  2 371
b  1.68
a  1.7 
1 100/760  3 971  2 414
a  1.65
b  3.1 
3
42  ♂  640 
(16 × 20) 
0/0  3 978  2 623
b  1.52
a  3.2 
1 100/760  3 987  2 691
a  1.48
b  2.5 
a,b Values in a column within one trial with a different superscript letter are significantly different (P < 0.05). 
4.1.  Conclusions on the efficacy 
The performance of chickens for fattening was significantly improved in three studies at the minimum 
recommended dose. Therefore, the FEEDAP Panel concludes that the additive has the potential to be 
efficacious in chickens for fattening at the minimum recommended dose. 
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This conclusion can be extended to chickens reared for laying. The mode of action of the enzymes 
glucanase and xylanase is well known and can be considered to be similar in all poultry species; thus, 
the conclusion on the efficacy in chickens for fattening can be extrapolated to minor poultry species 
for fattening or reared for laying. 
5.  Post-market monitoring 
The  FEEDAP  Panel  considers  that  there  is  no  need  for  specific  requirements  for  a  post-market 
monitoring  plan  other  than  those  established  in  the  Feed  Hygiene  Regulation
43  and  Good 
Manufacturing Practice. 
CONCLUSIONS 
The solid and liquid formulations are considered equivalent in terms of safety and efficacy for the 
target species. 
The additive does not give rise to safety concerns with regard to the genetic modification of one of the 
production  strains.  Neither  the  strain  nor  its  recombinant  DNA  was  detected  in  the  concentrate 
obtained from the genetically modified production strain. 
The additive is safe for chickens for fattening under the proposed conditions of use. This conclusion 
can be extended to chickens reared for laying and extrapolated to minor poultry species for fattening 
or reared for laying. 
The  products  of  fermentation  used  for  the  preparation  of  the  additive  gave  negative  results  for 
mutagenicity. The results obtained in sub-chronic oral toxicity studies raised no concerns regarding the 
products. Therefore, based on the toxicological studies performed with the fermentation products, the 
additive is of no concern regarding consumer safety. 
Rovabio
® Spiky AP and Rovabio
® Spiky LC are not irritants to the skin or eyes. In the absence of 
data, the additive should be considered a potential skin sensitiser and potentially harmful if inhaled. 
No risks to the environment are expected from the use of the additive in animal nutrition. 
The additive has the potential to be efficacious in chickens for fattening at the minimum recommended 
dose (1 100 U/kg xylanase and 760 U/kg glucanase). This conclusion can be extended to chickens 
reared for laying and extrapolated to minor poultry species for fattening or reared for laying. 
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EFSA Journal 2014;12(7):3793  19 
APPENDIX 
Executive Summary of the Evaluation Report of the European Union Reference Laboratory for 
Feed Additives on the Method(s) of Analysis for Rovabio
® Spiky
44,45 
In the current application authorisation is sought under article 4(1) for  Rovabio
® Spiky, under the 
category/functional  4(a)  "zootechnical  additives"/"digestibility  enhancers"  according  to  the 
classification system  of  Annex  I  of  Regulation (EC)  No  1831/2003.  Specifically,  authorisation  is 
sought for the use of the feed additive for chickens for fattening; chickens reared for laying and minor 
poultry species (for fattening and reared for laying).  
According to the Applicant, the feed additive contains two active substances: endo-1,4-beta-xylanase 
(EC 3.2.1.8) and endo-1,3 (4)-beta-glucanase (EC 3.2.1.6), produced from Talaromyces versatilis. The 
enzymatic activity for both enzymes is expressed by the Applicant in viscosity or in DNS units, where:  
- One xylanase (or beta-glucanase) viscosity unit (U) is defined as the amount of xylanase (or beta-
glucanase) that hydrolizes wheat arabinoxylan (or barley beta-glucan), reducing the solution viscosity, 
in order to change the relative fluidity by one dimensionless unit per minute, at pH 5.5 and 30 ºC.  
-  One  xylanase  (or  beta-glucanase)  DNS  unit  corresponds  to  the  amount  of  xylanase  (or  beta-
glucanase) which liberate from the birchwood xylan (or barley beta-glucan) one µmol of xylose (or 
glucose) per minute at 50 ºC and pH 4.0 (or pH 5.0).  
The product is intended to be marketed in powder (Rovabio
® Spiky AP) and liquid (Rovabio
® Spiky LC) 
formulations, having the following guaranteed minimum activities:  
- for xylanase: 22000 U/g or 2300 DNS units/g and 5500 U/ml or 570 DNS units /ml, and  
- for beta-glucanase: 15200 U/g or 1600 DNS units /g and 3800 U/ml or 400 DNS units /ml.  
The carrier in the solid formulation is wheat flour, while sorbitol, potassium sorbate and demineralized 
water  are  used  for  the  liquid  formulation.  The  feed  additive  is  intended  to  be  incorporated  into 
premixtures and/or complete feedingstuffs to obtain a minimum xylanase and beta-glucanase activity 
of 1100 and 760 U/kg, respectively.  
For the quantification of xylanase and beta-glucanase activities in the feed additive, premixtures and 
feedingstuffs, the Applicant submitted a single-laboratory validated and further verified viscosimetry 
methods.  Furthermore,  the  Applicant  submitted  alternative  colorimetric  (DNS)  methods  for  the 
quantification  of  xylanase  and  beta-glucanase  activities  in  the  feed  additive.  In  the  viscosimetry 
methods the endo-1,4-beta-xylanase (or the endo-1,3(4)-beta-glucanase) catalyses the hydrolysis of 
xylosidic (or glycosidic) bonds in the wheat arabinoxylan (or barley beta-glucan) substrate to yield 
xylose (or glucose) and reduces consequently the viscosity of the sample solution. The colorimetric 
methods are based on the enzymatic hydrolysis of the birchwood xylan (or barley beta-glucan) and the 
consequent colour formation of released sugar with 3,5-dinitrosalicylic acid (DNS) at pH 4.0 (or pH 
5.0)  and  50  ºC.  Based  on  the  acceptable  performance  characteristics  the  EURL  recommends  for 
official  control  the  validated  and  further  verified  viscosimetry  methods  for  the  determination  of 
xylanase  and  beta-glucanase  in  the  feed  additive,  premixtures  and  feedingstuffs  together  with  the 
alternative colorimetric (DNS) methods for the determination of xylanase and beta-glucanase in the 
feed additive.  
                                                       
44 The  full  report  is  available  on  the  EURL  website:  https://ec.europa.eu/jrc/sites/default/files/FinRep-FAD-2013-0030-
RovabioSpiky.pdf 
45   This section has been edited following the confidentiality claims made by the applicant. Rovabio
® Spiky for chickens  
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Further  testing  or  validation  of  the  methods to  be performed  through  the consortium  of  National 
Reference Laboratories as specified by Article 10 (Commission Regulation (EC) No 378/2005) is not 
considered necessary. 